- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01729949
The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)
A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)
- The primary objective is to determine the effect of fruit polyphenols on postprandial lipoprotein triglyceride metabolism after consumption a standard high carbohydrate/fat breakfast meal with a beverage rich in fruit-derived polyphenols compared to energy and macro-/micro-nutrient matched control beverage (acute, Part 1).
- Secondary objectives are: 1)to assess the effects of consuming daily for 8 weeks (chronic, Part 2) a beverage rich in fruit polyphenols compared to an energy and macro-/micro- nutrient matched control beverage on fasting glucose, insulin, lipids and markers of oxidative stress; and 2) to assess the effects of these beverages on meal-related changes in metabolic and oxidative stress measures after 8 weeks daily consumption.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a single-center, double-blinded, randomized, 2-part, 2-arm, 4-sequence, crossover study that incorporates both the acute and chronic evaluations of fruit polyphenols on metabolic indices and markers of oxidative stress.
A planned sample size of 30 overweight men and women will be recruited into the study. Subjects will be required to meet several inclusion and exclusion criteria, which will be assessed through online and clinic screening mechanisms, including questionnaires, blood analysis, and anthropometric measurements. Eligible subjects will be invited to participate in the study. Subjects will begin by completing a 7-day pre-study assessment of their usual dietary intake using 3-day food diary followed by washout of dietary polyphenols. Subjects will participate in 4, 6 h postprandial study days: 2 preceding the chronic intervention and 2 after 8 weeks each of active (fruit polyphenols) and placebo beverages. Subjects will be randomized on the first day of starting the acute and chronic study phases. Subjects will be asked to limit polyphenolic containing foods and beverages for 3 days prior to each 6 h postprandial study visit as well through the chronic dietary intervention. Subjects will be provided a standardized dinner meal pack on the day before each 6 h postprandial visit.
For each 6 h postprandial study visit, subjects will arrive fasted and follow procedures published by our lab previously. This includes: pre-study evaluation for compliance (fasting, dinner consumption, limited polyphenol intake) and readiness for study visit, catheter placement by registered nurse, fasting blood sample, consumption of high fat/carbohydrate meal accompanied by 1 of the two treatment beverages (active/fruit polyphenol or placebo beverage), subsequent blood sampling from catheter [ ~1 tablespoon (12ml)] at designated time points for 6 hours. Each postprandial study visit day will last approximately 7 hours and subjects will be required to remain at the Clinical Nutrition Research Center at the Illinois Institute of Technology main campus for the duration of the visit. The visit procedures are repeated twice ~ 1 week apart to accommodate subject testing with both beverages.
After completing both acute 6 h postprandial study visits, subjects will roll over to the chronic phase of the study and receive a 2nd randomization sequence for consuming the active or the placebo beverage daily for 8 weeks. Before crossing over to the alternative treatment beverage for another 8 weeks, subjects will have a 4-week break (wash out). Subjects will be counseled for a low polyphenolic diet throughout the study to consume the assigned beverage twice per day with lunch and evening meals (except during 4-week washout).
At the end of each week 8 treatment period, subjects will come to the research center for a 6 h postprandial study visit day: all procedures are identical on each postprandial study test visit with the exception that only the placebo beverage will be consumed with the breakfast.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- Clinical Nutrition Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-smoking healthy overweight or class I obesity adult men and women
- Age 40-65yr
- Weight stable
- Able to provide informed consent
- Able to comply and perform the procedures requested by the protocol.
Exclusion Criteria:
- Smokers or recent past smokers
- Men or women with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
- Diabetes
- Fasting blood glucose concentrations >125 mg/dL
- Fasting Total Cholesterol >250 mg/dL (6.47mmol/L)
- Fasting Triglycerides >250 mg/dL (2.82 mmol/L)
- Fasting LDL cholesterol >180 mg/dL (4.66 mmol/L)
- Uncontrolled blood pressure >140 mmHg/90 mmHg
- Documented vascular disease
- Cancer other than skin (non-melanoma) in previous 5 years
- Lactating and/or pregnant
- Taking medications or dietary supplements eg., antioxidant supplements, lipid lowering medication, blood pressure lowering medications.
- Recent blood donors (within 3 months)
- Vegans
- Substance (alcohol or drug) abuser (within the last 2 years)
- Participated in a chronic feeding or medication clinical trial in the last 3 months.
- Excessive coffee and tea consumers (> 4 cups/d)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Treatment Beverage
Strawberry powder and Blackcurrent extract
|
Strawberry and Blackcurrent extract
Other Names:
|
Placebo Comparator: Placebo Treatment Beverage
Placebo Beverage
|
without active components
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Plasma Triglycerides Concentrations
Time Frame: Acute Postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in Plasma Triglyceride concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC
|
Acute Postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Plasma Lipid and Lipoprotein panels
Time Frame: Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in Lipids (panel) and lipoprotein particle size/density by nuclear magnetic resonance (NMR)
|
Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in insulin concentrations
Time Frame: Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in Plasma insulin concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax
|
Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in LDL oxidation
Time Frame: Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in Plasma OxLDL concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, and Cmax
|
Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in F2-isoprostane concentrations
Time Frame: Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Changes in Plasma F2-isoprostane concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phases assessed by iAUC, total AUC, Cmax and TMax
|
Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in plasma glucose concentrations
Time Frame: Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).
|
Changes in Plasma glucose concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax
|
Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).
|
Changes in polyphenol anthocyanin concentrations
Time Frame: Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).
|
Changes in Plasma polyphenol anthocyanin concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax
|
Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Indika Edirisinghe, Ph.D, Illinois Instutute of Technology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PPF 2012-073
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Children's Hospital Los AngelesUniversity of Southern California; Tufts Medical CenterRecruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Khyber Medical University PeshawarRecruitingObesity, OverweightPakistan
-
National Taiwan University HospitalCompleted
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.RecruitingBody Weight | Overweight and ObesityCroatia
Clinical Trials on Active Treatment Beverage
-
Clinical Nutrition Research Center, Illinois Institute...CompletedHypercholesterolemia | Glycemic ResponseUnited States
-
PepsiCo Global R&DGlycemic Index Laboratories, IncCompleted
-
Ryerson UniversityCompleted
-
University of PrimorskaCompletedBlood Pressure | Energy Expenditure | Substrate OxidationSlovenia
-
Stanford UniversityNot yet recruiting
-
Boston VA Research Institute, Inc.United States Department of DefenseCompleted
-
Unilever R&DCompletedSatiety | AppetiteUnited Kingdom
-
Pennington Biomedical Research CenterCorby K. Martin; Owen T. CarmichaelCompleted
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); Indiana UniversityRecruitingAtrial FibrillationUnited States
-
Viveve Inc.CompletedFemale Sexual DysfunctionUnited States, Canada